Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Humanistic burden and health-related quality of life

7 evidence topics · 7 sources